Coxibs and cardiovascular disease.

Adverse Drug Reaction Reporting Systems Anti-Inflammatory Agents, Non-Steroidal/adverse effects,pharmacology Cardiovascular Diseases/chemically induced Celecoxib Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors/adverse effects,pharmacology Drug Approval Drug Industry Epoprostenol/antagonists & inhibitors Gastrointestinal Diseases/chemically induced Humans Isoenzymes/antagonists & inhibitors,metabolism Isoxazoles/adverse effects Lactones/adverse effects,pharmacology Membrane Proteins Naproxen/adverse effects Prostaglandin-Endoperoxide Synthases/metabolism Pyrazoles Risk Sulfonamides/adverse effects,pharmacology Sulfones Thromboxane A2/biosynthesis United States United States Food and Drug Administration

Anti-Inflammatory Agents, Non-Steroidal Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Isoenzymes Isoxazoles Lactones Membrane Proteins Pyrazoles Sulfonamides Sulfones rofecoxib valdecoxib Thromboxane A2 Naproxen Epoprostenol Cyclooxygenase 2 PTGS2 protein, human Prostaglandin-Endoperoxide Synthases Celecoxib